DBV Technologies SA (DBVT)
0.6669
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
0.662
0.00 (0.00%)
After-Hours: 20:00
DBV Technologies Free Cash Flow (Quarterly): -14.04M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -14.04M |
| September 30, 2023 | -19.62M |
| June 30, 2023 | -25.72M |
| March 31, 2023 | -20.95M |
| December 31, 2022 | -23.90M |
| September 30, 2022 | -20.42M |
| June 30, 2022 | -10.49M |
| March 31, 2022 | -1.614M |
| Date | Value |
|---|---|
| December 31, 2021 | -19.70M |
| September 30, 2021 | -22.94M |
| June 30, 2021 | -30.13M |
| March 31, 2021 | -36.39M |
| December 31, 2020 | -34.13M |
| September 30, 2020 | -43.00M |
| June 30, 2020 | -40.68M |
| March 31, 2020 | -50.61M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-50.61M
Minimum
Mar 2020
-1.614M
Maximum
Mar 2022
-25.90M
Average
-23.42M
Median
Free Cash Flow (Quarterly) Benchmarks
| Biophytis SA | -- |
| Edap TMS SA | -5.566M |
| Cellectis SA | 39.44M |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | -15.50M |